[
  {
    "ts": "2026-02-18T09:26:00+00:00",
    "headline": "Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035",
    "summary": "Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, boosting patient outcomes. Symptoms are often subtle, leading to underdiagnosis and treatment delays. The fallopian tube cancer market is driven by genetic testing demand, BRCA mutation screening, and advancements in targeted therapies like PARP inhibitors. Despite challenges, including high treatment",
    "url": "https://finance.yahoo.com/news/fallopian-tube-cancer-market-research-092600660.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6bf6abe8-13ab-3ffa-b94a-fbc329fb953f",
      "content": {
        "id": "6bf6abe8-13ab-3ffa-b94a-fbc329fb953f",
        "contentType": "STORY",
        "title": "Fallopian Tube Cancer Market Research Report 2026: AstraZeneca, GlaxoSmithKline, Pfizer and Roche Expand Portfolios and Invest in Novel Therapeutics & Companion Diagnostics - Forecasts 2025-2035",
        "description": "",
        "summary": "Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, boosting patient outcomes. Symptoms are often subtle, leading to underdiagnosis and treatment delays. The fallopian tube cancer market is driven by genetic testing demand, BRCA mutation screening, and advancements in targeted therapies like PARP inhibitors. Despite challenges, including high treatment",
        "pubDate": "2026-02-18T09:26:00Z",
        "displayTime": "2026-02-18T09:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fallopian-tube-cancer-market-research-092600660.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fallopian-tube-cancer-market-research-092600660.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T10:16:00+00:00",
    "headline": "$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)",
    "summary": "The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding oncology, rare disease, and diabetes pipelines, bolstered by peptide-based drugs like Semaglutide. In 2024, the pharmaceutical and biotechnology segment captured the largest market share, reinforced by in-house manufacturing of high-value drugs and increasing outsourcing for",
    "url": "https://finance.yahoo.com/news/198-39-bn-active-pharmaceutical-101600490.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "667d5d85-1890-3c02-8e2b-8151284ca38a",
      "content": {
        "id": "667d5d85-1890-3c02-8e2b-8151284ca38a",
        "contentType": "STORY",
        "title": "$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)",
        "description": "",
        "summary": "The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding oncology, rare disease, and diabetes pipelines, bolstered by peptide-based drugs like Semaglutide. In 2024, the pharmaceutical and biotechnology segment captured the largest market share, reinforced by in-house manufacturing of high-value drugs and increasing outsourcing for",
        "pubDate": "2026-02-18T10:16:00Z",
        "displayTime": "2026-02-18T10:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f17019bd7ddea4815dee288c80d9b7fe",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Active Pharmaceutical Ingredients (API) Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/82uh4eZvFTWMRxmA7hFB.Q--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f17019bd7ddea4815dee288c80d9b7fe.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/weD1LQLKgiMB6mDCx2zL8A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f17019bd7ddea4815dee288c80d9b7fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/198-39-bn-active-pharmaceutical-101600490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/198-39-bn-active-pharmaceutical-101600490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "TEVA"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]